Lina is the Vice President and Principal Scientist at Ayass Bioscience, LLC with the responsibility to oversee, manage, and lead daily operations in both the clinical and research laboratories. Prior to joining Ayass Bioscience, her career was focused on basic science research in academic institutions where she served as a faculty member. The opportunity presented at Ayass Bioscience allowed her to utilize her skills and dive into the world of translational research by bridging science to patient care. She is involved in the design, development, and validation of high complexity molecular testing from next generation sequencing to array-based genotyping assays. She is also part of a research team that utilizes nanotechnology for diagnostic applications, identifies and clinically validates new biomarkers for autoimmune disease, and develops aptamers for diagnostic and therapeutic applications in the fields of coagulation, allergy, cancer, and COVID-19.
Ayass Bioscience has been a pioneer in implementing artificial intelligence to predict patient outcome. It started with the development of ‘MoNet’, an advanced biological tool that uses CAI (Cognitive Artificial Intelligence) to collect and analyze data from hundreds of molecular tests conducted on thousands of patients at Ayass Bioscience to identify clinical associations between biomarkers and generate a prediction score for an individual’s risk of thrombosis. Lina had the privilege to be part of that project that opened the door for the development of Machine Learning Models for the prediction of patient outcome as it relates to cancer and metastasis. With data produced at an unprecedented rate, the new direction of Ayass Bioscience is to implement such tools to build models for prediction for better patient outcome in other disciplines of medicine such as immunology as well as in the biomedical research conducted.
Ayass Bioscience has been a pioneer in implementing artificial intelligence to predict patient outcome. It started with the development of ‘MoNet’, an advanced biological tool that uses CAI (Cognitive Artificial Intelligence) to collect and analyze data from hundreds of molecular tests conducted on thousands of patients at Ayass Bioscience to identify clinical associations between biomarkers and generate a prediction score for an individual’s risk of thrombosis. Lina had the privilege to be part of that project that opened the door for the development of Machine Learning Models for the prediction of patient outcome as it relates to cancer and metastasis. With data produced at an unprecedented rate, the new direction of Ayass Bioscience is to implement such tools to build models for prediction for better patient outcome in other disciplines of medicine such as immunology as well as in the biomedical research conducted.
Lina earned her Bachelor’s and Master’s in Cell Biology at the American University of Beirut in Lebanon. Upon moving to the U.S., Lina received her Ph.D. in Molecular Genetics and Biochemistry at the University of Texas Southwestern Medical Center at Dallas in the laboratory of Nobel laureates Drs. Michael S. Brown and Joseph L Goldstein.
Natalya is the Senior Scientist at Ayass Bioscience, LLC with the responsibility to oversee and manage high-complexity genetic testing and lead numerous research projects. She has multiple years of experience in biochemistry, molecular biology, microbiology, and molecular genetics in both academia and biotech industry settings.
At Ayass Bioscience, she is involved in the design, development, and validation of high-complexity molecular testing ranging from next generation sequencing to array-based genotyping assays. She is participating actively in a transcriptome sequencing project essential for interpreting the functional elements of the genome, revealing the molecular constituents of cells and tissues, and understanding development and disease.
Her major research project is the development of aptamers that bind a specific target molecule, or family of target molecules. She has successfully developed an aptamer for the detection of D-dimer levels in blood sample and a Thrombin aptamer as a potential anticoagulant agent. Recently, she led the project to develop stable and biologically active aptamers that inhibit SARS-CoV-2 infection. A series of single-stranded DNA aptamers has been developed to specifically bind to the trimeric S protein of SARS-CoV-2, blocking its interaction with the ACE2 receptor and consequently inhibiting infection. The selected aptamers could be an innovative therapy for the treatment of COVID-19.
She is also part of the proteomics team for identification and validation of new biomarkers for autoimmune diseases, cardiac diseases, coagulation, and other disorders.
Natalya earned her master’s degrees in Biophysics at Saint Petersburg State University in Saint Petersburg, Russia, and her Ph.D. in Molecular Biology at the Institute of Protein Research of the Russian Academy of Sciences. After receiving her Ph.D., Natalya worked as Senior Research Scientist at the Biological Center of Russian Academy of Sciences. Subsequently, she moved to the U.S. where she worked as a Research Scientist at the University of Texas, Dallas, and then worked as a Senior Research Scientist for a biotechnology company before joining Dr. Ayass’s team as their Molecular Biology scientist.
At Ayass Bioscience, she is involved in the design, development, and validation of high-complexity molecular testing ranging from next generation sequencing to array-based genotyping assays. She is participating actively in a transcriptome sequencing project essential for interpreting the functional elements of the genome, revealing the molecular constituents of cells and tissues, and understanding development and disease.
Her major research project is the development of aptamers that bind a specific target molecule, or family of target molecules. She has successfully developed an aptamer for the detection of D-dimer levels in blood sample and a Thrombin aptamer as a potential anticoagulant agent. Recently, she led the project to develop stable and biologically active aptamers that inhibit SARS-CoV-2 infection. A series of single-stranded DNA aptamers has been developed to specifically bind to the trimeric S protein of SARS-CoV-2, blocking its interaction with the ACE2 receptor and consequently inhibiting infection. The selected aptamers could be an innovative therapy for the treatment of COVID-19.
She is also part of the proteomics team for identification and validation of new biomarkers for autoimmune diseases, cardiac diseases, coagulation, and other disorders.
Natalya earned her master’s degrees in Biophysics at Saint Petersburg State University in Saint Petersburg, Russia, and her Ph.D. in Molecular Biology at the Institute of Protein Research of the Russian Academy of Sciences. After receiving her Ph.D., Natalya worked as Senior Research Scientist at the Biological Center of Russian Academy of Sciences. Subsequently, she moved to the U.S. where she worked as a Research Scientist at the University of Texas, Dallas, and then worked as a Senior Research Scientist for a biotechnology company before joining Dr. Ayass’s team as their Molecular Biology scientist.
Victor is a Research Scientist at Ayass Bioscience, LLC with the responsibility to conduct high-complexity genetic testing and participate in research projects. He has multiple years of experience as a biomedical research scientist with expertise in molecular biology, molecular genetics, and biochemistry. He is involved in the design, development, and validation of high-complexity genetic testing such as Pharmacogenetics and Hereditary Cancer Assessment. He demonstrates advanced skills in biological and biotechnological systems through the optimization of several protocols for DNA and RNA extraction, PCR, genotyping by mass-spectrometry, and data analysis.
Victor is a valuable member of the Ayass Bioscience research team. He participates in all research projects utilizing his knowledge in biochemistry, immunochemistry, and molecular biology. He is one of the key scientists working on the Aptamer project. He contributed significantly to the development of aptamers for detecting D-dimer levels in blood samples and Thrombin aptamers as a potential anticoagulant agent. In recent times, he played a major role in a project aimed at developing stable and biologically active aptamers for inhibiting SARS-CoV-2 infection. A set of single-stranded DNA aptamers has been developed to bind selectively to the trimeric S protein of SARS-CoV-2, disrupting its interaction with the ACE2 receptor and thereby hindering infection. He has shown that selected aptamers were not only able to bind to trimer S protein of Wuhan original strain, but also were able to bind to trimer S proteins of Delta, Delta plus, Alpha, Lambda, Mu, and Omicron and inhibit their binding to ACE2 receptor in Vero E6 cell line. These carefully chosen aptamers hold promise as an innovative therapeutic approach for managing COVID-19.
Victor earned his Master’s degree in Biophysics at Lomonosov Moscow State University and his Ph.D. in Biochemistry at Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences. Victor worked in the Biological Center of the Russian Academy of Sciences. After he moved to the U.S., he held a research scientist position at the Cornell University Medical Center and at the UT Southwestern Medical Center. He joined the Ayass BioScience team as a Research Scientist.
Victor is a valuable member of the Ayass Bioscience research team. He participates in all research projects utilizing his knowledge in biochemistry, immunochemistry, and molecular biology. He is one of the key scientists working on the Aptamer project. He contributed significantly to the development of aptamers for detecting D-dimer levels in blood samples and Thrombin aptamers as a potential anticoagulant agent. In recent times, he played a major role in a project aimed at developing stable and biologically active aptamers for inhibiting SARS-CoV-2 infection. A set of single-stranded DNA aptamers has been developed to bind selectively to the trimeric S protein of SARS-CoV-2, disrupting its interaction with the ACE2 receptor and thereby hindering infection. He has shown that selected aptamers were not only able to bind to trimer S protein of Wuhan original strain, but also were able to bind to trimer S proteins of Delta, Delta plus, Alpha, Lambda, Mu, and Omicron and inhibit their binding to ACE2 receptor in Vero E6 cell line. These carefully chosen aptamers hold promise as an innovative therapeutic approach for managing COVID-19.
Victor earned his Master’s degree in Biophysics at Lomonosov Moscow State University and his Ph.D. in Biochemistry at Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences. Victor worked in the Biological Center of the Russian Academy of Sciences. After he moved to the U.S., he held a research scientist position at the Cornell University Medical Center and at the UT Southwestern Medical Center. He joined the Ayass BioScience team as a Research Scientist.
Kevin is part of the Bioinformatics team at Ayass Bioscience, where he works to improve understanding of clinical data through computational and statistical methods. As a member of the Ayass Bioscience team, he manages the data and data analysis for various projects at the company, including aptamer research, development of genetic and other lab-developed tests, proteomics research, and many others, along with providing consultation on the computational aspects of these projects. He also helps to prepare SOPs and validation reports for some of the tests, as well as assisting in identifying targets for testing of various diseases. Additionally, Kevin conducts statistical analysis on the results from clinical laboratory tests, providing insight into the connections between biomarkers and identifying trends among the patient populations. He has developed software tools both to help analyze data from various sources as well as to improve efficiency in various aspects of the business and is one of the primary contributors to the development of the MoNet software. He is involved in the marketing parts of company as well, helping to arrange direct-to-consumer products and prepare informational resources.
He joined Ayass Bioscience after receiving his Bachelor’s in Computational and Applied Mathematics from Rice University and his Master’s in Bioinformatics from the University of Texas Health Science Center at Houston.
Jin is the epidemiologist at Ayass Bioscience, LLC with the responsibility to provide research design and methodological experience on clinical data analysis. Before joining Ayass Bioscience, she worked for the University of Texas Southwestern Medical Center on HIV cluster detection and public health response.
The opportunity presented by Ayass Bioscience enabled her to put her expertise in experimental design, planning, data analysis, modeling and projections, bioanalytical parameter determinations, and validation of various assays and clinical sample bioanalysis. She is working on the research of the discovery of biomarkers in COVID-19 diagnostic testing.
Jin received her M.D. degree from the school of Medicine, China Three Gorges University, China. She earned her Master’s degree in Pharmacology and Toxicology from the University of Mississippi Medical Center and MPH degree in Epidemiology and Biostatistics from the School of Public Health, Jackson State University after moving to the United States.
The opportunity presented by Ayass Bioscience enabled her to put her expertise in experimental design, planning, data analysis, modeling and projections, bioanalytical parameter determinations, and validation of various assays and clinical sample bioanalysis. She is working on the research of the discovery of biomarkers in COVID-19 diagnostic testing.
Jin received her M.D. degree from the school of Medicine, China Three Gorges University, China. She earned her Master’s degree in Pharmacology and Toxicology from the University of Mississippi Medical Center and MPH degree in Epidemiology and Biostatistics from the School of Public Health, Jackson State University after moving to the United States.
Dr. Trivendra Tripathi (Flow Cytometry Scientist) has expertise in designing and validating clinical flow cytometry assays for immunophenotyping in leukemia and lymphoma, profiling and subsetting cells such as lymphocytes (T cells and B cells), stem cells, myeloid cells, macrophage and monocyte subpopulations, intracellular staining, and rare cell detection. He is part of the R&D team at Ayass Bioscience and is involved in developing in vitro diagnosis and targeting therapies for many diseases.
Dr. Tripathi is also responsible for designing an immune profile flow cytometry panel for COVID-19 patients and correlating the findings to mass spectrometry.
Before joining Ayass Bioscience, Dr. Tripathi worked at AbeXXa Biologics, Inc. His prior appointment was as a Senior Research Fellow at Mayo Clinic, Scottsdale, AZ. He also received postdoctoral training from UNT Health Science Center at Fort Worth and Baylor Institute for Immunology Research, BSWRI at Dallas. Dr Tripathi earned his Ph.D. degree in Biochemistry at Aligarh Muslim University, India. He also holds a Master of Science degree in Biotechnology from CSJM University, India and a Bachelor of Science (Hons.) degree in Chemistry from AMU, India.
Dr. Ramya is Researcher at Ayass Bioscience LLC, focused on executing and validating profile flow cytometry panels for COVID-19 patients. She is part of the Aptamer development team and responsible for optimizing and validating the efficiency of Aptamers to the target molecules using cell culture assays and flow cytometry.
Ramya has obtained her Doctorate from Cochin University of Science and Technology, India, for her studies on using molecular techniques in the field of environmental science. Ramya has done research in utilizing metagenomic, metatranscriptomics, metaproteomics, bioinformatics and multivariate statistical analysis to understand the expression of genes and their functions. Ramya completed her Masters in Biotechnology from Bharathiar University, India and her project was focused on identification of complement proteins using native 2D PAGE electrophoresis. Ramya has joined the Ayass Bioscience LLC in September 2021, after her doctorate and has been part of the Ayass research and development team.
Tutku earned her bachelor’s degree in bio engineering from both Montana State University and Istanbul Technical University with a dual degree program. Then, she pursued her master’s degree and graduated Fall 2019 from Montana State University with a master’s degree in Immunology and Infectious Diseases. During her education, she worked as a Research Assistant in Lei Lab in Montana State University. In Lei Lab Tutku conducted research on pathogenesis of Group A Streptococcus virulence factors, ScpA and SpeB, where she learned valuable professional skills such as recombinant DNA construction, creating site-directed mutagenesis, interpreting the sequence alignments, protein purification by using ion exchange chromatography and so on. Also, Tutku have gained experience working with pulmonary mouse models. Fall 2019, she worked as a Teaching Assistant for Human Anatomy and Physiology II Lab, where she gained the ability to lead and teach students. Tutku joined Ayass BioScience Research team in February, 2020 as a Research Technician and involved in DNA extraction from human biological samples for next generation sequencing, performed SDS page gel, Western-Blot Analysis, immunoprecipitation, Pierce Rapid Gold BCA and Micro BCA Protein Assays. She is currently responsible of viral RNA extraction of COVID-19 patient samples and the detection of SARS-CoV-2 in extracted patients’ samples by using RT-qPCR technique.
If you have any questions about Ayass BioScience, LLC Team or their qualifications, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.
